HIK Overzicht aandelen
Hikma Pharmaceuticals PLC ontwikkelt, produceert, verkoopt en verhandelt een reeks generieke farmaceutische producten, merkproducten en farmaceutische producten onder licentie. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 6/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 5/6 |
Beloningen
Risicoanalyse
Hikma Pharmaceuticals PLC Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | UK£18.72 |
| 52 Week Hoogtepunt | UK£21.65 |
| 52 Week Laag | UK£17.11 |
| Bèta | 0.44 |
| 11 maand verandering | -6.49% |
| 3 maanden verandering | -7.05% |
| 1 Jaar Verandering | 6.79% |
| 33 jaar verandering | -19.03% |
| 5 jaar verandering | -3.26% |
| Verandering sinds IPO | 563.83% |
Recent nieuws en updates
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Recent updates
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28Rendement voor aandeelhouders
| HIK | GB Pharmaceuticals | GB Markt | |
|---|---|---|---|
| 7D | 4.3% | -2.3% | 0.7% |
| 1Y | 6.8% | -2.8% | 6.1% |
Rendement versus industrie: HIK overtrof de UK Pharmaceuticals industrie, die het afgelopen jaar een rendement -2.8 % opleverde.
Rendement versus markt: HIK kwam overeen met de UK markt, die het afgelopen jaar een rendement opleverde van 6.1 %.
Prijsvolatiliteit
| HIK volatility | |
|---|---|
| HIK Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stabiele aandelenkoers: HIK heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van HIK is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1978 | 9,100 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC ontwikkelt, produceert, verkoopt en verhandelt een reeks generieke en merkgeneesmiddelen en farmaceutische producten onder licentie. Het bedrijf is actief in drie segmenten: Injectables, Generics en Branded. Het segment Injectables levert generische injecteerbare producten, voornamelijk voor gebruik in ziekenhuizen.
Hikma Pharmaceuticals PLC Samenvatting
| HIK fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | UK£4.09b |
| Inkomsten(TTM) | UK£225.51m |
| Inkomsten(TTM) | UK£2.39b |
18.4x
Koers/Winstverhouding1.7x
P/S-verhoudingIs HIK overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| HIK resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$3.02b |
| Kosten van inkomsten | US$1.57b |
| Brutowinst | US$1.45b |
| Overige uitgaven | US$1.16b |
| Inkomsten | US$285.00m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.29 |
| Brutomarge | 47.99% |
| Nettowinstmarge | 9.45% |
| Schuld/Eigen Vermogen Verhouding | 53.2% |
Hoe presteerde HIK op de lange termijn?
Bekijk historische prestaties en vergelijking